Vaccines in the 21st century

Western Journal of Medicine

Volumn 171, Issue 5-6, 1999, Pages 319-322

  Liu, Margaret A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0041625804     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Guleria I, Teitelbaum R, McAdam RA, et al. Auxotrophic vaccines for tuberculosis. Nature Med 1996;2:334-37.
2. Levine MM, Galen J, Barry E, Noriega F, Chatfield S, Sztein M, et al. Attenuated salmonella as live oral vaccines against typhoid fever and as live vectors. J Biotechnol. 1996;44:193-196.
3. Ferrari G, Humphrey W, McElrath MJ, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA. 1997;94:1396-1401.
4. Polo JM, Belli BA, Driver DA, et al. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci USA. 1999;96:4598-4603.
5. Donnelly JJ, Ulmer JB, Shiver JW, et al., DNA vaccines. Annu Rev Immunol. 1997;15:617-648.
6. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med. 1998;338:1405-1412.
7. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influe nza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282:137-144.
8. Giuliani MM, Del Giudice G, Giannelli V, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med. 1998;187:1123-1132.
9. Douce G, Turcotte C, Cropley I, et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Nad Acad Sci USA. 1995;92:1644-1648.
10. Kotloff KL, Noriega F, Losonsky GA, et al. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun. 1996;64:4542-4548.
11. Tacket CO, Kelly SM, Schodel F, et al. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun. 1997;65:3381-3385. (Correction in Infect Immun 1997;65:3981)
12. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization. Vaccine. 1997;15:804-847.
13. Hone DM, Wu S, Powell RJ, et al. Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. J Biotechnol. 1996;44:203-207.
14. Mason HS, Ball JM, Shi JJ, et al. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA. 1996;93:5335-5340.
15. Tacket CO, Mason HS, Losonsky G, et al. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nature Med 1998;4:607-609.
16. Glenn GM, Rao M, Matyas GR, et al. Skin immunization made possible by cholera toxin. Nature. 1998;391:851.
17. Minutello M, Senatore F, Cecchinelli G, et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine. 1999;17:99-104.
18. O'Hagan DT. Recent advances in vaccine adjuvants for systemic and mucosal administration. J Pharm Pharmacol. 1998;50:1-10.